Sanofi's 15min chart shows Bollinger Bands expanding downward, bearish marubozu signal.

Sanofi's 15-minute chart displays an expanding downward trend in Bollinger Bands, coupled with a bearish Marubozu pattern observed at 11:00 on September 2, 2025. This indicates that the market is currently dominated by sellers, and a continuation of bearish momentum is expected.

Sanofi shares surged by 0.9% on the Paris Stock Exchange following a significant upgrade from Deutsche Bank analysts. The upgrade, driven by optimism over amlitelimab, a new treatment for atopic dermatitis, has led Deutsche Bank to raise its recommendation and target price to €110, indicating a 22% upside potential [1].

The analysts at Deutsche Bank have upgraded their recommendation for Sanofi shares from "hold" to "buy," citing an "attractive risk/reward" ahead of key trial results for amlitelimab. The optimism is rooted in the potential of amlitelimab to replace Dupixent, Sanofi's flagship drug, which accounts for nearly half of its pharmaceutical revenues. However, the patent for Dupixent is set to expire in 2031, creating a significant risk for the company's stock market valuation [2].

Deutsche Bank believes that amlitelimab, with its imminent Phase 3 data in atopic dermatitis, could take over from Dupixent, as this condition represents more than 70% of Dupixent's current revenues. The analysts have raised their price target for Sanofi shares to €110, a 22% increase from their previous target, highlighting the potential for amlitelimab to significantly boost the company's revenues. The stock is currently trading at a valuation multiple of 11x earnings, which Deutsche Bank believes is relatively low compared to the risk involved [2].

The upgrade from Deutsche Bank reflects growing optimism among investors about Sanofi's ability to diversify its revenue streams and mitigate the risks associated with the expiration of its flagship drug's patent. The upcoming Phase 3 results for amlitelimab will be closely watched by investors, as they could significantly impact the company's future prospects.

References:
[1] https://www.ainvest.com/news/sanofi-deutsche-bank-upgrades-buy-recommendation-hold-hold-2509/
[2] https://www.ainvest.com/news/sanofi-shares-rise-deutsche-bank-upgrade-target-price-set-110-2509/